Clinical Trial

Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score

Study acronym: TEAMMATE
Completed Phase 3
View on ClinicalTrials.gov →
Summary
The TEAMMATE Trial will enroll 210 pediatric heart transplant patients from 25 centers at 6 months post-transplant and follow each patient for 2.5 years. Half of the participants will receive everolimus and low-dose tacrolimus and the other half will receive tacrolimus and mycophenolate mofetil. The trial will determine which treatment is better at reducing the cumulative risk of coronary artery vasculopathy, chronic kidney disease and biopsy proven-acute cellular rejection without an increase in graft loss due to all causes (e.g. infection, PTLD, antibody mediated rejection).
Protocol Amendment History 2 changes
critical Trial completed 2026-08-01
minor Completion moved earlier: 2024-01 -> 2023-05-17 2026-08-01
Trial Details
NCT Number NCT03386539
Lead Sponsor Boston Children's Hospital
Collaborators: Stanford University, United States Department of Defense
Conditions Pediatric Heart Transplantation, Immunosuppression, Chronic Kidney Diseases, Cardiac Allograft Vasculopathy, Heart Transplant Failure and Rejection, Post-transplant Lymphoproliferative Disorder, Heart Transplant Infection
Enrollment 211 participants
Start Date 2018-01-29
Primary Completion 2023-04-17 (estimated)
Study Completion 2023-05-17 (estimated)
Updated on ClinicalTrials.gov 2026-07-31